Peer-reviewedCC BY-NCThoracic Research and Practice
Reply: Comparative Clinical Outcomes of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis: A Five-Year Real-Life Study
- 1Department of Chest Diseases Aydın Adnan Menderes University Faculty of Medicine, Aydın, Türkiye
Related
- Deep learning–based quantification of CT changes after 1 year of pirfenidone treatment as a prognostic marker in idiopathic pulmonary fibrosis
- Absolute and lung volume-normalized deep learning-derived pulmonary vascular measures in idiopathic pulmonary fibrosis: distinct clinical associations and the role of lung volume in prognosis
- Nomogram models integrating multiregion radiomics, quantitative computed tomography, and clinical indicators for distinguishing connective tissue disease-associated interstitial lung disease from idiopathic pulmonary fibrosis and improving the prediction of gender-age-physiology stage
- Association of the Charlson Comorbidity Index and Age-Adjusted Charlson Comorbidity Index with Clinical Course and Mortality in Patients with Idiopathic Pulmonary Fibrosis
- Updates on the Translational Value of Idiopathic Pulmonary Fibrosis Models Across Species: Deeper Insights Through Comparative Pathology
BibTeX
@article{yanalak2026reply,
title = {{Reply: Comparative Clinical Outcomes of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis: A Five-Year Real-Life Study}},
author = {Ayça Yanalak and Onur Yazıcı},
journal = {Thoracic Research and Practice},
year = {2026},
month = nov,
doi = {10.4274/thoracrespract.2026.2026-8-14},
url = {https://doi.org/10.4274/thoracrespract.2026.2026-8-14},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Reply: Comparative Clinical Outcomes of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis: A Five-Year Real-Life Study
AU - Ayça Yanalak
AU - Onur Yazıcı
PY - 2026
DA - 2026/11/09
JO - Thoracic Research and Practice
DO - 10.4274/thoracrespract.2026.2026-8-14
UR - https://doi.org/10.4274/thoracrespract.2026.2026-8-14
SN - 2979-9139
ER -